SUGATAB® – MV1Forte / MV2Forte Tablet

SUGATAB® – MV1Forte / MV2Forte is a triple fixed-dose combination specially developed for patients with type 2 diabetes mellitus (T2DM) who are not achieving glycemic control with dual therapy. It combines the insulin secretagogue action of Glimepiride, the insulin-sensitizing effect of Metformin, and the postprandial glucose-lowering action of Voglibose 0.3mg — a higher-strength alpha-glucosidase inhibitor for enhanced control of sugar spikes after meals.

Categories: ,

Description

Composition (Each Film-Coated Tablet Contains):

  • MV1Forte: Glimepiride 1 mg + Metformin Hydrochloride 500 mg + Voglibose I.P. 0.3 mg

  • MV2Forte: Glimepiride 2 mg + Metformin Hydrochloride 500 mg + Voglibose I.P. 0.3 mg

Category: Diabetes Care / Triple Oral Antidiabetic Therapy
Form: Oral Tablet
Pack Size: 10×10 Alu-Alu or Blister Pack


Product Description:

SUGATAB® – MV1Forte / MV2Forte is a triple fixed-dose combination specially developed for patients with type 2 diabetes mellitus (T2DM) who are not achieving glycemic control with dual therapy. It combines the insulin secretagogue action of Glimepiride, the insulin-sensitizing effect of Metformin, and the postprandial glucose-lowering action of Voglibose 0.3mg — a higher-strength alpha-glucosidase inhibitor for enhanced control of sugar spikes after meals.


Key Benefits:

  • Triple-mechanism therapy for comprehensive glycemic control

  • Stronger postprandial glucose management with Voglibose 0.3mg

  • Controls fasting and post-meal blood sugar effectively

  • Helps reduce HbA1c with low risk of long-term complications

  • Suitable for patients with uncontrolled or progressive T2DM


How it works:

  • Glimepiride stimulates insulin release from pancreatic beta cells in a glucose-dependent manner

  • Metformin reduces hepatic glucose production and enhances peripheral glucose uptake

  • Voglibose delays carbohydrate absorption in the intestine, reducing post-meal sugar spikes

Together, these agents provide multi-targeted control of blood glucose, improving both metabolic stability and quality of life in T2DM patients.


How to use:

  • Take one tablet twice daily, before the two largest meals of the day, or as advised by your physician

  • Swallow whole with water — do not split or chew

  • Avoid skipping meals after dosing

  • Monitor blood sugar levels regularly for optimal control


Safety Advice:

  • Mild bloating or flatulence may occur initially due to Voglibose

  • Risk of hypoglycemia increases if meals are skipped — always take with food

  • Avoid alcohol and monitor kidney and liver function during treatment

  • Adhere to dietary recommendations and hydration guidelines


Precautions:

  • Not recommended for type 1 diabetes or diabetic ketoacidosis (DKA)

  • Use with caution in patients with renal or hepatic impairment, gastrointestinal disorders, or elderly patients

  • Not advised during pregnancy or breastfeeding unless prescribed by a physician

  • Inform your doctor about any other antidiabetic medications, insulin, or supplements in use


Storage:

Store in a cool, dry place below 25°C.
Protect from direct sunlight and moisture.
Keep out of reach of children.

Reviews

There are no reviews yet.

Be the first to review “SUGATAB® – MV1Forte / MV2Forte Tablet”

Your email address will not be published. Required fields are marked *